Invention Grant
- Patent Title: Glucagon receptor modulators
-
Application No.: US14471576Application Date: 2014-08-28
-
Publication No.: US09073871B2Publication Date: 2015-07-07
- Inventor: Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent James T. Wasicak
- Main IPC: A61K31/415
- IPC: A61K31/415 ; C07D231/12 ; C07D207/34 ; C07D231/14 ; C07D231/16 ; C07D231/18 ; C07D231/54 ; C07D231/56 ; C07D233/61 ; C07D233/64 ; C07D233/68 ; C07D233/70 ; C07D233/84 ; C07D249/06 ; C07D249/08 ; C07D261/08 ; C07D401/04 ; C07D401/12 ; C07D401/14 ; C07D403/04 ; C07D405/14 ; C07D487/04 ; C07D403/12

Abstract:
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Public/Granted literature
- US20140371467A1 GLUCAGON RECEPTOR MODULATORS Public/Granted day:2014-12-18
Information query